Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging.
multimodality imaging
optical imaging
polymeric nanoparticles
positron emission tomography
single-domain antibodies
targeting
Journal
Small (Weinheim an der Bergstrasse, Germany)
ISSN: 1613-6829
Titre abrégé: Small
Pays: Germany
ID NLM: 101235338
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
03
09
2019
revised:
15
11
2019
pubmed:
28
12
2019
medline:
7
5
2021
entrez:
28
12
2019
Statut:
ppublish
Résumé
Active tumor targeting involves the decoration of nanomaterials (NMs) with oncotropic vector biomolecules that selectively recognize certain antigens on malignant cells or in the tumor microenvironment. This strategy can facilitate intracellular uptake of NM through specific interactions such as receptor-mediated endocytosis and can lead to prolonged retention in the malignant tissues by preventing rapid efflux from the tumor. Here, the design of actively targeting, renally excretible bimodal dendritic polyglycerols (dPGs) for diagnostic cancer imaging is described. Single-domain antibodies (sdAbs) specifically binding to the epidermal growth factor receptor (EGFR) are employed herein as targeting warheads owing to their small size and high affinity for their corresponding antigen. The dPGs equipped with EGFR-targeting feature are compared head-to-head with their nontargeting counterparts in terms of interaction with EGFR-overexpressing cells in vitro as well as accumulation at receptor-positive tumors in vivo. Experimental results reveal a higher specificity and preferential tumor accumulation for the α-EGFR dPGs, resulting from the introduction of active targeting capabilities on their backbone. These results highlight the potential for improving the tumor uptake properties of dPGs by strategic use of sdAb functionalization, which can ultimately prove useful to the development of ultrasmall NM with highly specific tumor accumulation.
Identifiants
pubmed: 31880080
doi: 10.1002/smll.201905013
doi:
Substances chimiques
Polymers
0
Single-Domain Antibodies
0
polyglycerol
25618-55-7
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Glycerol
PDC6A3C0OX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1905013Informations de copyright
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
a) A. G. Arranja, V. Pathak, T. Lammers, Y. Shi, Pharmacol. Res. 2017, 115, 87;
b) D. Rosenblum, N. Joshi, W. Tao, J. M. Karp, D. Peer, Nat. Commun. 2018, 9, 1410;
c) V. Sanna, N. Pala, M. Sechi, Int. J. Nanomed. 2014, 9, 467;
d) J. Y. Yhee, S. Lee, K. Kim, Nanoscale 2014, 6, 13383;
e) S. Kunjachan, J. Ehling, G. Storm, F. Kiessling, T. Lammers, Chem. Rev. 2015, 115, 10907;
f) G. Chen, I. Roy, C. Yang, P. N. Prasad, Chem. Rev. 2016, 116, 2826.
a) H. Maeda, Adv. Enzyme Regul. 2001, 41, 189;
b) Y. Matsumura, H. Maeda, Cancer Res. 1986, 46, 6387.
a) N. Bertrand, J. Wu, X. Xu, N. Kamaly, O. C. Farokhzad, Adv. Drug Delivery Rev. 2014, 66, 2;
b) J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, Nat. Rev. Cancer 2017, 17, 20;
c) H. Maeda, Adv. Drug Delivery Rev. 2015, 91, 3;
d) Q. Sun, T. Ojha, F. Kiessling, T. Lammers, Y. Shi, Biomacromolecules 2017, 18, 1449.
a) F. Danhier, J. Controlled Release 2016, 244, 108;
b) S. K. Golombek, J. N. May, B. Theek, L. Appold, N. Drude, F. Kiessling, T. Lammers, Adv. Drug Delivery Rev. 2018, 130, 17;
c) F. Man, T. Lammers, R. T. M. de Rosales, Mol. Imaging Biol. 2018, 20, 683;
d) M. Torrice, ACS Cent. Sci. 2016, 2, 434;
e) T. Lammers, F. Kiessling, M. Ashford, W. Hennink, D. Crommelin, G. Storm, Nat. Rev. Mater. 2016, 1, 16069;
f) R. van der Meel, T. Lammers, W. E. Hennink, Expert Opin. Drug Delivery 2017, 14, 1;
g) A. Nel, E. Ruoslahti, H. Meng, ACS Nano 2017, 11, 9567;
h) U. Prabhakar, H. Maeda, R. K. Jain, E. M. Sevick-Muraca, W. Zamboni, O. C. Farokhzad, S. T. Barry, A. Gabizon, P. Grodzinski, D. C. Blakey, Cancer Res. 2013, 73, 2412;
i) K. L. Swetha, A. Roy, Drug Delivery Transl. Res. 2018, 8, 1508.
a) F. Chen, E. B. Ehlerding, W. Cai, J. Nucl. Med. 2014, 55, 1919;
b) R. Bazak, M. Houri, S. El Achy, S. Kamel, T. Refaat, J. Cancer Res. Clin. Oncol. 2015, 141, 769;
c) T. Lammers, F. Kiessling, W. E. Hennink, G. Storm, J. Controlled Release 2012, 161, 175;
d) J. D. Byrne, T. Betancourt, L. Brannon-Peppas, Adv. Drug Delivery Rev. 2008, 60, 1615.
K. Zarschler, L. Rocks, N. Licciardello, L. Boselli, E. Polo, K. P. Garcia, L. De Cola, H. Stephan, K. A. Dawson, Nanomedicine 2016, 12, 1663.
M. Talekar, J. Kendall, W. Denny, S. Garg, Anti-Cancer Drugs 2011, 22, 949.
K. F. Pirollo, E. H. Chang, Trends Biotechnol. 2008, 26, 552.
a) S. Kunjachan, R. Pola, F. Gremse, B. Theek, J. Ehling, D. Moeckel, B. Hermanns-Sachweh, M. Pechar, K. Ulbrich, W. E. Hennink, G. Storm, W. Lederle, F. Kiessling, T. Lammers, Nano Lett. 2014, 14, 972;
b) R. Singh, M. Norret, M. J. House, Y. Galabura, M. Bradshaw, D. Ho, R. C. Woodward, T. G. St Pierre, I. Luzinov, N. M. Smith, L. Y. Lim, K. S. Iyer, Small 2016, 12, 351;
c) N. Schleich, C. Po, D. Jacobs, B. Ucakar, B. Gallez, F. Danhier, V. Preat, J. Controlled Release 2014, 194, 82.
a) Y. Hu, C. Liu, S. Muyldermans, Front. Immunol. 2017, 8, 1442;
b) S. Muyldermans, Annu. Rev. Biochem. 2013, 82, 775;
c) C. Vincke, S. Muyldermans, Methods Mol. Biol. 2012, 911, 15.
a) J. van Loon, A. J. G. Even, H. Aerts, M. Ollers, F. Hoebers, W. van Elmpt, L. Dubois, A. C. Dingemans, R. I. Lalisang, P. Kempers, B. Brans, V. Winnepenninckx, E. J. Speel, E. Thunnissen, K. M. Smits, R. Boellaard, D. J. Vugts, D. De Ruysscher, P. Lambin, Radiother. Oncol. 2017, 122, 267;
b) C. W. Menke-van der Houven van Oordt, E. C. Gootjes, M. C. Huisman, D. J. Vugts, C. Roth, A. M. Luik, E. R. Mulder, R. C. Schuit, R. Boellaard, O. S. Hoekstra, G. A. van Dongen, H. M. Verheul, Oncotarget 2015, 6, 30384;
c) B. A. Hoeben, J. D. Molkenboer-Kuenen, W. J. Oyen, W. J. Peeters, J. H. Kaanders, J. Bussink, O. C. Boerman, Int. J. Cancer 2011, 129, 870;
d) J. M. Warram, E. de Boer, A. G. Sorace, T. K. Chung, H. Kim, R. G. Pleijhuis, G. M. van Dam, E. L. Rosenthal, Cancer Metastasis Rev. 2014, 33, 809.
a) M. Bourgeois, C. Bailly, M. Frindel, F. Guerard, M. Cherel, A. Faivre-Chauvet, F. Kraeber-Bodere, C. Bodet-Milin, Expert Opin. Biol. Ther. 2017, 17, 813;
b) J. De Vos, N. Devoogdt, T. Lahoutte, S. Muyldermans, Expert Opin. Biol. Ther. 2013, 13, 1149.
H. S. Choi, W. Liu, P. Misra, E. Tanaka, J. P. Zimmer, B. Itty Ipe, M. G. Bawendi, J. V. Frangioni, Nat. Biotechnol. 2007, 25, 1165.
a) L. O. Gainkam, L. Huang, V. Caveliers, M. Keyaerts, S. Hernot, I. Vaneycken, C. Vanhove, H. Revets, P. De Baetselier, T. Lahoutte, J. Nucl. Med. 2008, 49, 788;
b) K. Zarschler, K. Prapainop, E. Mahon, L. Rocks, M. Bramini, P. M. Kelly, H. Stephan, K. A. Dawson, Nanoscale 2014, 6, 6046;
c) K. Zarschler, S. Witecy, F. Kapplusch, C. Foerster, H. Stephan, Microb. Cell Fact. 2013, 12, 97.
a) K. E. Conrath, M. Lauwereys, M. Galleni, A. Matagne, J. M. Frere, J. Kinne, L. Wyns, S. Muyldermans, Antimicrob. Agents Chemother. 2001, 45, 2807;
b) K. Broos, M. Keyaerts, Q. Lecocq, D. Renmans, T. Nguyen, D. Escors, A. Liston, G. Raes, K. Breckpot, N. Devoogdt, Oncotarget 2017, 8, 41932;
c) M. Lemaire, M. D'Huyvetter, T. Lahoutte, E. Van Valckenborgh, E. Menu, E. De Bruyne, P. Kronenberger, U. Wernery, S. Muyldermans, N. Devoogdt, K. Vanderkerken, Leukemia 2014, 28, 444;
d) C. Xavier, A. Blykers, I. Vaneycken, M. D'Huyvetter, J. Heemskerk, T. Lahoutte, N. Devoogdt, V. Caveliers, Nucl. Med. Biol. 2016, 43, 247.
T. Joshi, M. Kubeil, A. Nsubuga, G. Singh, G. Gasser, H. Stephan, ChemPlusChem 2018, 83, 554.
a) A. Sunder, R. Hanselmann, H. Frey, R. Mülhaupt, Macromolecules 1999, 32, 4240;
b) K. Pant, D. Gröger, R. Bergmann, J. Pietzsch, J. Steinbach, B. Graham, L. Spiccia, F. Berthon, B. Czarny, L. Devel, V. Dive, H. Stephan, R. Haag, Bioconjugate Chem. 2015, 26, 906;
c) F. Paulus, M. E. R. Weiss, D. Steinhilber, A. N. Nikitin, C. Schütte, R. Haag, Macromolecules 2013, 46, 8458;
d) D. Gröger, F. Paulus, K. Licha, P. Welker, M. Weinhart, C. Holzhausen, L. Mundhenk, A. D. Gruber, U. Abram, R. Haag, Bioconjugate Chem. 2013, 24, 1507.
F. Sheikhi Mehrabadi, J. Adelmann, S. Gupta, S. Wedepohl, M. Calderón, U. Brinkmann, R. Haag, Curr. Cancer Drug Targets 2016, 16, 639.
M. Calderon, P. Welker, K. Licha, I. Fichtner, R. Graeser, R. Haag, F. Kratz, J. Controlled Release 2011, 151, 295.
E. Blanco, H. Shen, M. Ferrari, Nat. Biotechnol. 2015, 33, 941.
a) H. Frey, R. Haag, J. Biotechnol. 2002, 90, 257;
b) M. Calderon, M. A. Quadir, S. K. Sharma, R. Haag, Adv. Mater. 2010, 22, 190;
c) J. Khandare, A. Mohr, M. Calderon, P. Welker, K. Licha, R. Haag, Biomaterials 2010, 31, 4268.
a) B. R. Lee, E. Jo, H. Y. Yoon, C. J. Yoon, H. J. Lee, K. C. Kwon, T. W. Kim, J. Lee, Adv. Sci. 2018, 5, 1800494;
b) S. E. Kim, S. D. Jo, K. C. Kwon, Y. Y. Won, J. Lee, Adv. Sci. 2017, 4, 1600471;
c) B. Godin, C. Chiappini, S. Srinivasan, J. F. Alexander, K. Yokoi, M. Ferrari, P. Decuzzi, X. Liu, Adv. Funct. Mater. 2012, 22, 4225;
d) S. A. Love, M. A. Maurer-Jones, J. W. Thompson, Y. S. Lin, C. L. Haynes, Annu. Rev. Anal. Chem. 2012, 5, 181.
K. Pant, J. Pufe, K. Zarschler, R. Bergmann, J. Steinbach, S. Reimann, R. Haag, J. Pietzsch, H. Stephan, Nanoscale 2017, 9, 8723.
a) R. C. Roovers, T. Laeremans, L. Huang, S. De Taeye, A. J. Verkleij, H. Revets, H. J. de Haard, P. M. van Bergen en Henegouwen, Cancer Immunol. Immunother. 2007, 56, 303;
b) R. C. Roovers, M. J. Vosjan, T. Laeremans, R. el Khoulati, R. C. de Bruin, K. M. Ferguson, A. J. Verkleij, G. A. van Dongen, P. M. van Bergen en Henegouwen, Int. J. Cancer 2011, 129, 2013;
c) K. Zarschler, K. Zscheppang, F. Kapplusch, N. Cordes, H. Stephan, Nucl. Med. Biol. 2014, 41, 628.
a) M. Yu, J. Zheng, ACS Nano 2015, 9, 6655;
b) M. Longmire, P. L. Choyke, H. Kobayashi, Nanomedicine 2008, 3, 703.
a) X. Jiang, C. Rocker, M. Hafner, S. Brandholt, R. M. Dorlich, G. U. Nienhaus, ACS Nano 2010, 4, 6787;
b) S. Reichert, P. Welker, M. Calderon, J. Khandare, D. Mangoldt, K. Licha, R. K. Kainthan, D. E. Brooks, R. Haag, Small 2011, 7, 820;
c) A. Albanese, C. D. Walkey, J. B. Olsen, H. Guo, A. Emili, W. C. Chan, ACS Nano 2014, 8, 5515;
d) Y. Yan, K. T. Gause, M. M. Kamphuis, C. S. Ang, N. M. O'Brien-Simpson, J. C. Lenzo, E. C. Reynolds, E. C. Nice, F. Caruso, ACS Nano 2013, 7, 10960;
e) E. Casals, T. Pfaller, A. Duschl, G. J. Oostingh, V. Puntes, ACS Nano 2010, 4, 3623.
S. Albert, C. Arndt, S. Koristka, N. Berndt, R. Bergmann, A. Feldmann, M. Schmitz, J. Pietzsch, J. Steinbach, M. Bachmann, Oncotarget 2018, 9, 25597.
K. R. Schmitz, A. Bagchi, R. C. Roovers, P. M. van Bergen en Henegouwen, K. M. Ferguson, Structure 2013, 21, 1214.
a) G. Gasser, L. Tjioe, B. Graham, M. J. Belousoff, S. Juran, M. Walther, J. U. Künstler, R. Bergmann, H. Stephan, L. Spiccia, Bioconjugate Chem. 2008, 19, 719;
b) R. Bergmann, A. Ruffani, B. Graham, L. Spiccia, J. Steinbach, J. Pietzsch, H. Stephan, Eur. J. Med. Chem. 2013, 70, 434.
a) K. Zarschler, M. Kubeil, H. Stephan, RSC Adv. 2014, 4, 10157;
b) M. C. Linder, L. Wooten, P. Cerveza, S. Cotton, R. Shulze, N. Lomeli, Am. J. Clin. Nutr. 1998, 67, 965S.
X. Liang, H. Wang, Y. Zhu, R. Zhang, V. C. Cogger, X. Liu, Z. P. Xu, J. E. Grice, M. S. Roberts, ACS Nano 2016, 10, 387.
a) A. F. Hussain, H. R. Krüger, F. Kampmeier, T. Weissbach, K. Licha, F. Kratz, R. Haag, M. Calderon, S. Barth, Biomacromolecules 2013, 14, 2510;
b) F. S. Mehrabadi, J. Adelmann, S. Gupta, S. Wedepohl, M. Calderon, U. Brinkmann, R. Haag, Curr. Cancer Drug Targets 2016, 16, 639.
a) Y. Shi, T. Lammers, Acc. Chem. Res. 2019, 52, 1543;
b) T. Carter, P. Mulholland, K. Chester, Immunotherapy 2016, 8, 941.
A. Haider, K. Zarschler, S. A. Joshi, R. M. Smith, Z. Lin, A. S. Mougharbel, U. Herzog, C. E. Müller, H. Stephan, U. Kortz, Z. Anorg. Allg. Chem. 2018, 644, 752.
U. K. Laemmli, Nature 1970, 227, 680.
a) M. Kreller, H. J. Pietzsch, M. Walther, H. Tietze, P. Kaever, T. Knieß, F. Füchtner, J. Steinbach, S. Preusche, Instruments 2019, 3, 9;
b) S. Hoberück, G. Wunderlich, E. Michler, T. Hölscher, M. Walther, D. Seppelt, I. Platzek, K. Zöphel, J. Kotzerke, J. Labelled Compd. Radiopharm. 2019, 62, 523.
C. Neuber, B. Belter, S. Meister, F. Hofheinz, R. Bergmann, H. J. Pietzsch, J. Pietzsch, Molecules 2018, 23, 444.
M. Laube, M. Frizler, R. Wodtke, C. Neuber, B. Belter, T. Kniess, M. Bachmann, M. Gutschow, J. Pietzsch, R. Löser, J. Labelled Compd. Radiopharm. 2019, 62, 448.